Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Terminated 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 6Squamous Cell Carcinoma of Head and Neck 5Carcinoma, Renal Cell 5Carcinoma, Non-Small-Cell Lung 5Colorectal Neoplasms 3Neoplasms 2Lung Neoplasms 2Hodgkin Disease 2Head and Neck Neoplasms 2Carcinoma, Transitional Cell 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Turcot syndrome 1Solid Tumors 1Skin Neoplasms 1Sarcoma, Kaposi 1Sarcoma 1Recurrence 1Rare Tumour 1Prostatic Neoplasms 1Post-Acute COVID-19 Syndrome 1Pancreatic Neoplasms 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Mouth Neoplasms 1Medulloblastoma 1Lung Diseases, Interstitial 1Liver Neoplasms 1Fibrolamellar hepatocellular carcinoma 1Ependymoma 1

Interventions

fludarabine 1cemiplimab 1Temozolomide 1Nivolumab 1Histocompatibility Testing 1Etoposide 1Cyclophosphamide 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Ependymoma × Nivolumab × Clear all
NCT06639607 2026-06-03

PRiME II

Washington University School of Medicine

Phase 1/2 Not yet recruiting
68 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Ependymoma, Medulloblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡